Insider · CIK 0001237409
Timothy C Barabe
Files at RNAC (Cartesian Therapeutics, Inc.), HTFL (Heartflow, Inc.). First filing Dec 8, 2025, latest Dec 8, 2025.
Timothy C Barabe files SEC Form 4 as director at RNAC (Cartesian Therapeutics, Inc.), and also at HTFL (Heartflow, Inc.). Since Dec 8, 2025, Timothy C Barabe has reported 1 open-market buy worth $206k and 0 open-market sells worth $0, the latest filed on Dec 8, 2025.
A track record needs three past buys with six months of prices behind them; Timothy C Barabe has 0, so none is measured yet.
The newest scored trade: bought $206k of RNAC on Dec 4, 2025, filed Dec 8, 2025, scored 55 (moderate). In the last 12 months: 1 buy worth $206k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNAC: Cartesian Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | RNACbuy Cartesian Therapeutics, Inc. | $206k 30,000 shares | +123% | +4% from low-73% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | HTFL Heartflow, Inc. | AGrant or award Stock Optionderivative | +16,075 | $32.05 | $515k | 16,075 | Jun 18, 2026 |
| Mar 11, 2026 | HTFL Heartflow, Inc. | MOption exercise Common Stock | +8,667 | $2.22 | $19k | 179,521 | Mar 12, 2026 |
| Mar 11, 2026 | HTFL Heartflow, Inc. | MOption exercise Stock Optionderivative | -8,667 | $0.00 | $0 | 15,412 | Mar 12, 2026 |
| Feb 17, 2026 | HTFL Heartflow, Inc. | MOption exercise Common Stock | +2,497 | $8.33 | $21k | 170,854 | Feb 19, 2026 |
| Feb 17, 2026 | HTFL Heartflow, Inc. | MOption exercise Stock Optionderivative | -2,497 | $0.00 | $0 | 0 | Feb 19, 2026 |
| Jan 2, 2026 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Common Stock | +2,600 | $0.00 | $0 | 56,966 | Jan 6, 2026 |
| Jan 2, 2026 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +7,800 | $0.00 | $0 | 7,800 | Jan 6, 2026 |
| Dec 4, 2025 | RNAC Cartesian Therapeutics, Inc. | POpen-market purchase Common Stock | +30,000 | $6.86 | $206k | 54,366 | Dec 8, 2025 |
| Aug 11, 2025 | HTFL Heartflow, Inc. | CConversion Common Stock | +131,578 | - | - | 168,357 | Aug 11, 2025 |
| Aug 7, 2025 | HTFL Heartflow, Inc. | AGrant or award Stock Optionderivative | +23,710 | $0.00 | $0 | 23,710 | Aug 11, 2025 |
| Aug 11, 2025 | HTFL Heartflow, Inc. | CConversion Convertible Promissory Notederivative | -131,578 | $0.00 | $0 | 0 | Aug 11, 2025 |
| Jan 2, 2025 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Common Stock | +2,600 | $0.00 | $0 | 24,366 | Jan 6, 2025 |
| Jan 2, 2025 | RNAC Cartesian Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +7,800 | $0.00 | $0 | 7,800 | Jan 6, 2025 |
Questions about Timothy C Barabe
Answered from the filings on this page, as of the latest one.
Is Timothy C Barabe buying or selling?
In the last 12 months Timothy C Barabe reported 1 open-market buy worth $206k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $206k of RNAC on Dec 4, 2025. Grants, option exercises and tax withholding are not counted.
How did Timothy C Barabe's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Timothy C Barabe has 0.
Where does Timothy C Barabe file Form 4?
Timothy C Barabe has filed Form 4 at RNAC (Cartesian Therapeutics, Inc.); HTFL (Heartflow, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.